CARsgen Therapeutics Holdings Ltd

CARsgen Therapeutics disclosed its first-half 2026 results, reporting revenue of 62 million yuan, mainly from its autologous BCMA CAR-T product Zevorcabtagene Autoleucel. Thanks to higher sales of Zevorcabtagene Autoleucel, gross profit reached 42 million yuan, up 13 million yuan from 29 million yuan in the same period of 2025. Net loss for the period was 70.84 million yuan, compared with annual net losses of 748 million yuan, 798 million yuan and 98 million yuan from 2023 to 2025. With the approval in June 2026 of the world's first solid tumor CAR-T product, Satricabtagene Autoleucel, the market expects it to add new volume in the second half. Satricabtagene Autoleucel is listed at 990,000 yuan per dose. The company expects 200 orders in 2026 and forecasts peak sales of 2 billion yuan in the mainland China market, reaching that peak in about four to five years. As of the end of June 2026, the company had cash and cash equivalents of about 1.4 billion yuan, up 277 million yuan from 1.123 billion yuan at the end of 2025. The company judges that its existing capital reserves can support operations until 2030.